MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Multimodal imaging Integrating 18F-APN-1607 and 18F-FP-DTBZ PET in Progressive Supranuclear Palsy

C. Dong, J. Ma, S. Liu (Beijing, China)

Meeting: 2025 International Congress

Keywords: Progressive supranuclear palsy(PSP)

Category: MSA, PSP, CBS: Neuroimaging

Objective: To identify the regions with sensitive tau deposition for differentiating progressive supranuclear palsy (PSP) from healthy controls. Additionally, to explore the combination of ​18F-APN-1607 for detecting tau aggregates and 18F-FP-DTBZ positron emission tomography (PET) for assessing dopaminergic disruption.

Background: As a neurodegenerative disorder characterized by pathological tau protein deposition, tau deposition in PSP can be evaluated by tau PET. Meanwhile, nigrostriatal presynaptic imaging is used to assess dopaminergic impairment in PSP.

Method: A subset of 20 PSP patients with dopaminergic impairment identified via 18F-FP-DTBZ PET were selected from the CHINA cohort and subsequently underwent 18F-APN-1607 PET. Images were spatially normalized and analyzed according to the volume of interest. ​An erosion-based cerebral white matter was applied as the reference region for calculating the standardized uptake value ratios (SUVRs).

Results: The SUVRs of the pallido-nigro-luysian axis demonstrated the most significant differences between patients with PSP and healthy controls (pallidum: 1.552±0.172 vs. 1.305±0.124, P=0.002; substantia nigra: 1.454±0.217 vs. 1.239±0.094, P=0.001; subthalamic nucleus: 1.619±0.218 vs. 1.255±0.178, P<0.001). Tau PET positivity was defined as Z-scores >2 in two different regions of all defined cortical and subcortical regions. Tau PET positivity was observed in 16 out of 20 patients. Specifically, 9 out of 20 patients showed positive results concurrently in the frontal and temporal cortices. The differences of ​18F-FP-DTBZ PET between patients with PSP and healthy controls are mainly reflected in the caudate, putamen, and substantia nigra. The correlation analysis showed that there was no significant correlation between tau burden of the pallido-nigro-luysian axis and the nigrostriatal dopaminergic impairment. Among 4 patients with negative tau PET findings, 3 patients had the caudate SUVRs of ​18F-FP-DTBZ PET that were below the diagnostic threshold for differentiating progressive supranuclear palsy (PSP) from Parkinson’s disease (PD), as measured by our PSP-​18F-FP-DTBZ cohort.

Conclusion: The pallido-nigro-luysian axis serves as a sensitive target for detecting tau deposition in PSP. The combination of ​18F-APN-1607 and ​18F-FP-DTBZ PET can offer complementary imaging information for PSP.

Figure 1

Figure 1

To cite this abstract in AMA style:

C. Dong, J. Ma, S. Liu. Multimodal imaging Integrating 18F-APN-1607 and 18F-FP-DTBZ PET in Progressive Supranuclear Palsy [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/multimodal-imaging-integrating-18f-apn-1607-and-18f-fp-dtbz-pet-in-progressive-supranuclear-palsy/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/multimodal-imaging-integrating-18f-apn-1607-and-18f-fp-dtbz-pet-in-progressive-supranuclear-palsy/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley